27/05/2026 TG Therapeutics announced positive topline results from Phase 3 trial in adults with relapsing form of multiple sclerosis TG Therapeutics announced positive topline results from Phase 3 trial in adults with relapsing form of multiple sclerosis (Ref) TG Therapeutics announced positive topline results from the Phase 3, ENHANCE trial of BRIUMVI® (ublituximab-xiiy; anti-CD20) in adults with relapsing form of multiple sclerosis (RMS). The trial met its primary endpoint,

14/05/2026 Filing of Gazyva for additional indication of Idiopathic Nephrotic Syndrome Filing of Gazyva for additional indication of Idiopathic Nephrotic Syndrome (Ref) Chugai Pharmaceutical and Nippon Shinyaku announced that Chugai had filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for Gazyva® (obinutuzumab; anti-CD20) for intravenous infusion 1000 mg for an additional indication of idiopathic nephrotic syndrome (INS). The filing was ba

16/02/2026 Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy ( Ref ) Roche announced positive results from the Phase 3 MAJESTY/ NCT04629248 study which evaluated the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab; anti-CD20) in patients with primary membranous nephropathy The study met its primary endpoint of complete remission at t